TPO · Fully Adhered
75,000 sqft Cold Storage Facility
Sqft75K
System80-mil TPO FA
Timeline10 days
Commercial roofing for pharmaceutical manufacturing, biotech facilities, cleanroom-adjacent spaces, and FDA-audited medical device facilities across NC, SC, GA, TN — with particular focus on Research Triangle Park concentration. Fully-adhered TPO, cGMP-documented workflow, Part 11 electronic records.
A licensed PM has your request. We'll reach out within 24 business hours — typically sooner. If your roof is actively leaking, call (866) 487-8572 for same-day response.
The NC Research Triangle has been a pharmaceutical and biotech hub since the 1980s, but the expansion wave from 2021 forward has been larger than any prior. Eli Lilly announced $1B expansion at RTP. Amgen $1B facility in Holly Springs. Novo Nordisk $6B expansion across multiple sites. FUJIFILM Diosynth ongoing biomanufacturing capacity expansion. Grifols, Merck KGaA, and dozens of clinical-stage biotechs building or expanding manufacturing. The total pharmaceutical and biotech manufacturing capacity in NC has grown roughly 40% in the last 4 years.
Pharmaceutical and biotech facility roofing is the most regulatorily complex commercial roofing work. FDA 21 CFR cGMP requirements, cleanroom environmental controls, validated manufacturing envelopes, and Part 11 electronic recordkeeping combine to demand workflow discipline that generic commercial roofers aren't prepared for. A roofing contractor who triggers an FDA 483 observation (inspection finding) costs the building owner far more than the roof scope.
We focus on pharmaceutical and biotech specifically because the operational discipline — cGMP-aligned contractor procedures, cleanroom HVAC coordination, change control documentation, Part 11 electronic records, and enhanced insurance matching regulatory risk — is a narrow qualification set. Most pharmaceutical facility engineering teams maintain a small approved contractor list; we work to stay on those lists through documented project track record and audit-ready documentation.
Typical pharma and biotech projects: active manufacturing facilities (Lilly, Novo Nordisk, Amgen, FUJIFILM Diosynth — 75K-250K sqft, cleanroom-adjacent or cleanroom-rooftop), clinical-stage biomanufacturing (25K-75K sqft, less cleanroom-intensive but full cGMP envelope), pharmaceutical warehouse and packaging (40K-150K sqft, lower regulatory intensity), and medical device manufacturing (21 CFR Part 820 requirements differ from Part 211 but similar workflow discipline). Every project integrates with facility Quality System and documentation requirements. Pharma facilities share envelope-control operational DNA with cold storage (vapor barrier integrity critical) and food processing (regulated contamination prevention) — our workflow transfers directly.
Installed cost runs $11–20 per square foot depending on facility type, regulatory envelope, and cleanroom coordination complexity. Ranges reflect cGMP-compliant workflow, Part 11 documentation, and enhanced insurance structure. Vaccine and biologics facilities trend toward upper range.
Every pharmaceutical facility roof replacement integrates with facility Quality System, cGMP compliance, and (for cleanroom-adjacent work) validated environmental envelope. Our process follows facility-specific change control and documentation requirements.
Drone survey + facility walk with facility QA, facility engineering, and validation team. Review of facility Quality System, environmental monitoring requirements, and manufacturing schedule. Identification of validated envelope boundaries and cleanroom-adjacent zones. Written contractor work procedure drafted and filed with QA before mobilization. Detailed bid in 48 hours with fully-adhered TPO spec and cGMP-coordinated sequencing.
Project crew completes documented cGMP awareness training. Change control package prepared documenting any specification changes from existing roof system. Environmental monitoring baseline established before work begins. Facility-specific security and access protocols verified.
Rooftop HVAC unit operation coordinated with facility engineering. Cleanroom pressure differentials monitored; any work affecting HVAC sequenced to cleanroom validation windows. Zones torn off phased and dried-in within single work shift. Zero exposure to manufacturing areas during active production runs.
Polyiso insulation installed to R-25 minimum (R-30 for facilities with refrigerated or humidity-controlled interior spaces). Vapor barrier continuity maintained. 80-mil TPO fully-adhered with zero mechanical fasteners through field membrane. Field seams heat-welded at 1,100°F with robotic welder; every seam probe-tested. Double-membrane construction where spec'd.
Every penetration field-detailed with pre-molded or custom-fabricated flashings. HEPA-filter supply and return penetrations (for cleanroom HVAC) detailed with specific engineering-approved flashing profiles. Environmental monitoring verification post-installation — pressure differentials, HVAC functionality, and environmental parameters confirmed within validated envelope.
Manufacturer NDL warranty registered (up to 30 years). Enhanced documentation package with Part 11-compliant electronic records: photos of every seam and penetration, as-built drawings, environmental verification records, change control documentation, training records. Handoff meeting with facility QA, facility engineering, and validation team.
cGMP-compliant roof replacements at pharmaceutical manufacturing, biotech, and medical device facilities across NC (RTP-focused), SC, GA, TN. Zero validation excursions on 100% of projects.
FDA 21 CFR Part 211 (Current Good Manufacturing Practice for pharmaceuticals) requires documented procedures for all work affecting manufacturing operations, written training records for personnel in GMP environments, environmental control and monitoring, and change control for any modification to validated processes or facilities. Roof work doesn't typically require FDA pre-approval but must be documented through the facility's Quality System.
21 CFR Part 820 (Quality System Regulation for medical devices) follows similar requirements for medical device facilities. Devices classified as Class II or III carry more stringent requirements; Class I less so. We work to Part 820 documentation standards on medical device facility projects.
21 CFR Part 11 (Electronic Records and Electronic Signatures) applies to any electronic records supporting FDA-regulated operations. Our project documentation uses Part 11-capable systems (DocuSign for signatures, Procore for project management with audit trails) so our documentation integrates with facility QA systems without creating compliance gaps.
USP 797, 800, 825, and 1116 (pharmacy compounding, hazardous drugs, radiopharmaceuticals, microbiological environmental monitoring) may apply to specific pharmaceutical manufacturing contexts. These are facility-specific requirements we coordinate with facility QA during project scoping.
For controlled substance manufacturing (Schedule I-V per DEA regulations), DEA security requirements add additional facility access and documentation layers. Our work on DEA-registered facilities follows facility security officer protocols matching DEA requirements. System spec for pharma facilities typically centers on 80-mil fully-adhered TPO for zero-penetration membrane integrity, with occasional EPDM specification for legacy retrofits where building envelope preservation is paramount.
FDA cGMP-compliant workflow, cleanroom HVAC coordination, Part 11 electronic documentation, enhanced insurance matching regulatory risk. 48-hour bid with change control documentation.